Data is not available at this time.
Comprehensive Healthcare Systems Inc. operates as a specialized healthcare technology provider, developing customized administrative software solutions for the North American healthcare market. The company's core revenue model centers on licensing proprietary software platforms and providing ongoing maintenance services to a diverse client base. Its comprehensive suite addresses critical administrative functions including membership card management, disease tracking, pre-certification workflows, claims processing, and electronic bill payment systems. This positions CHS as an integrated solution provider within the healthcare information services sector, catering primarily to unions, self-insured employee benefit funds, insurance carriers, and third-party administrators. The company's strategic focus on serving these niche B2B segments differentiates it from broader consumer-facing health tech firms. By targeting organizations that manage complex healthcare benefits, CHS addresses specific pain points related to administrative efficiency and compliance. Its market position is that of a specialized vendor offering tailored solutions rather than off-the-shelf products, which allows for deeper client integration and potentially higher retention rates despite operating in a competitive landscape dominated by larger healthcare IT providers.
For the fiscal year, the company reported revenue of CAD 3.77 million while recording a net loss of CAD 0.61 million. The negative profitability reflects ongoing operational challenges in achieving scale. However, the business generated positive operating cash flow of CAD 0.37 million, indicating some capacity to fund operations from core activities. Capital expenditures of CAD 0.33 million were nearly covered by operating cash generation, suggesting disciplined investment in maintaining its software platform.
The diluted EPS of -CAD 0.098 demonstrates current earnings weakness as the company works toward sustainable profitability. The modest positive operating cash flow relative to revenue indicates some efficiency in converting sales to cash, though overall capital efficiency remains constrained by the net loss position. The business model requires balancing software development costs against licensing revenue, with scale needed to improve margins.
The balance sheet shows limited liquidity with cash equivalents of just CAD 11,028 against total debt of CAD 2.50 million. This significant debt burden relative to cash reserves presents substantial financial risk. The high leverage ratio indicates potential constraints on operational flexibility and investment capacity, requiring careful management of creditor relationships and cash flow timing to maintain solvency.
Current financial metrics do not indicate strong growth momentum, with the company focused on stabilizing operations rather than expansion. The dividend policy is non-existent, with zero dividends paid, reflecting the company's loss-making position and priority of conserving cash for operational needs and debt obligations. All available capital is being directed toward sustaining the business rather than shareholder returns.
With a market capitalization of approximately CAD 11.31 million, the market appears to be assigning some speculative value to the company's technology platform despite current financial challenges. The exceptionally high beta of 2.91 indicates extreme volatility and significant sensitivity to market movements, suggesting investor perception of substantial risk alongside potential upside if operational turnaround occurs.
The company's primary strategic advantage lies in its specialized software solutions tailored to specific healthcare administrative needs. However, the outlook remains challenging given the constrained balance sheet and ongoing losses. Success will depend on the company's ability to secure additional client contracts to drive revenue growth while managing its substantial debt load. The healthcare IT sector's ongoing digital transformation provides potential tailwinds, but execution risk remains elevated.
Company financial statementsTSXV filings
show cash flow forecast
| Fiscal year | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | 2034 | 2035 | 2036 | 2037 | 2038 | 2039 | 2040 | 2041 | 2042 | 2043 | 2044 | 2045 | 2046 | 2047 | 2048 | 2049 | |
INCOME STATEMENT | ||||||||||||||||||||||||||
| Revenue growth rate, % | NaN | |||||||||||||||||||||||||
| Revenue, $ | NaN | |||||||||||||||||||||||||
| Variable operating expenses, $m | NaN | |||||||||||||||||||||||||
| Fixed operating expenses, $m | NaN | |||||||||||||||||||||||||
| Total operating expenses, $m | NaN | |||||||||||||||||||||||||
| Operating income, $m | NaN | |||||||||||||||||||||||||
| EBITDA, $m | NaN | |||||||||||||||||||||||||
| Interest expense (income), $m | NaN | |||||||||||||||||||||||||
| Earnings before tax, $m | NaN | |||||||||||||||||||||||||
| Tax expense, $m | NaN | |||||||||||||||||||||||||
| Net income, $m | NaN | |||||||||||||||||||||||||
BALANCE SHEET | ||||||||||||||||||||||||||
| Cash and short-term investments, $m | NaN | |||||||||||||||||||||||||
| Total assets, $m | NaN | |||||||||||||||||||||||||
| Adjusted assets (=assets-cash), $m | NaN | |||||||||||||||||||||||||
| Average production assets, $m | NaN | |||||||||||||||||||||||||
| Working capital, $m | NaN | |||||||||||||||||||||||||
| Total debt, $m | NaN | |||||||||||||||||||||||||
| Total liabilities, $m | NaN | |||||||||||||||||||||||||
| Total equity, $m | NaN | |||||||||||||||||||||||||
| Debt-to-equity ratio | NaN | |||||||||||||||||||||||||
| Adjusted equity ratio | NaN | |||||||||||||||||||||||||
CASH FLOW | ||||||||||||||||||||||||||
| Net income, $m | NaN | |||||||||||||||||||||||||
| Depreciation, amort., depletion, $m | NaN | |||||||||||||||||||||||||
| Funds from operations, $m | NaN | |||||||||||||||||||||||||
| Change in working capital, $m | NaN | |||||||||||||||||||||||||
| Cash from operations, $m | NaN | |||||||||||||||||||||||||
| Maintenance CAPEX, $m | NaN | |||||||||||||||||||||||||
| New CAPEX, $m | NaN | |||||||||||||||||||||||||
| Total CAPEX, $m | NaN | |||||||||||||||||||||||||
| Free cash flow, $m | NaN | |||||||||||||||||||||||||
| Issuance/(repurchase) of shares, $m | NaN | |||||||||||||||||||||||||
| Retained Cash Flow, $m | NaN | |||||||||||||||||||||||||
| Pot'l extraordinary dividend, $m | NaN | |||||||||||||||||||||||||
| Cash available for distribution, $m | NaN | |||||||||||||||||||||||||
| Discount rate, % | NaN | |||||||||||||||||||||||||
| PV of cash for distribution, $m | NaN | |||||||||||||||||||||||||
| Current shareholders' claim on cash, % | NaN |